AU2007318922C1 - Pyrimidine derivatives as POSH and POSH-AP inhibitors - Google Patents

Pyrimidine derivatives as POSH and POSH-AP inhibitors Download PDF

Info

Publication number
AU2007318922C1
AU2007318922C1 AU2007318922A AU2007318922A AU2007318922C1 AU 2007318922 C1 AU2007318922 C1 AU 2007318922C1 AU 2007318922 A AU2007318922 A AU 2007318922A AU 2007318922 A AU2007318922 A AU 2007318922A AU 2007318922 C1 AU2007318922 C1 AU 2007318922C1
Authority
AU
Australia
Prior art keywords
compound
posh
alkyl
aryl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007318922A
Other languages
English (en)
Other versions
AU2007318922B2 (en
AU2007318922A1 (en
Inventor
Itzchak Angel
Maxim Borovitov
Nurit Livnah
Philippe Nakache
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteologics Ltd
Original Assignee
Proteologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteologics Ltd filed Critical Proteologics Ltd
Publication of AU2007318922A1 publication Critical patent/AU2007318922A1/en
Publication of AU2007318922B2 publication Critical patent/AU2007318922B2/en
Application granted granted Critical
Publication of AU2007318922C1 publication Critical patent/AU2007318922C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2007318922A 2006-11-07 2007-11-07 Pyrimidine derivatives as POSH and POSH-AP inhibitors Ceased AU2007318922C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85737806P 2006-11-07 2006-11-07
US60/857,378 2006-11-07
US95983107P 2007-07-17 2007-07-17
US60/959,831 2007-07-17
PCT/IL2007/001356 WO2008056356A2 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as posh and posh-ap inhibitors

Publications (3)

Publication Number Publication Date
AU2007318922A1 AU2007318922A1 (en) 2008-05-15
AU2007318922B2 AU2007318922B2 (en) 2013-01-10
AU2007318922C1 true AU2007318922C1 (en) 2013-09-12

Family

ID=39364907

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007318922A Ceased AU2007318922C1 (en) 2006-11-07 2007-11-07 Pyrimidine derivatives as POSH and POSH-AP inhibitors

Country Status (6)

Country Link
US (2) US8283355B2 (enExample)
EP (1) EP2083826A4 (enExample)
JP (1) JP2010509205A (enExample)
AU (1) AU2007318922C1 (enExample)
CA (1) CA2668859A1 (enExample)
WO (1) WO2008056356A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120116425A (ko) * 2009-11-30 2012-10-22 프로테오로직스 엘티디 작은 피리미딘 유도체 및 이의 사용 방법
WO2013088445A1 (en) * 2011-12-13 2013-06-20 Proteologics Ltd Pyrimidine derivatives for treatment of inflammatory diseases
GB201415688D0 (en) * 2014-09-04 2014-10-22 Univ Edinburgh Method and Systems
SG10201913958QA (en) * 2015-07-15 2020-03-30 Agency Science Tech & Res Modulation of hepatitis b virus replication
WO2018085208A1 (en) 2016-11-02 2018-05-11 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting tsg101-ubiquitin interaction
MA53086B1 (fr) * 2018-07-05 2024-07-31 Bayer Aktiengesellschaft Thiophènecarboxamides substitués et analogues comme agents antibactériens
US20220193041A1 (en) * 2019-04-02 2022-06-23 Yonsei University, University - Industry Foundation (UIF) Novel compound and method for preventing or treating of respiratory diseases comprising the same as an active ingredient
CN110760597B (zh) * 2019-11-22 2022-08-23 西北农林科技大学 一种检测黄牛ncstn基因拷贝数变异的方法及其应用
TW202527955A (zh) * 2023-11-27 2025-07-16 美商尼坎醫療公司 用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014807A1 (en) * 2004-07-19 2006-01-19 Lin Leu-Fen H Neuroprotective small organic molecules, compositions and uses related thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5734081A (en) 1994-08-05 1998-03-31 Warner-Lambert Company Arylthio compounds
JP2004515235A (ja) 2000-12-08 2004-05-27 ノボ ノルディスク アクティーゼルスカブ Ｔｆｆペプチド
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
CA2456754A1 (en) * 2001-08-08 2003-02-20 Yuji Iizawa Benzazepine derivative, process for producing the same, and use
FR2845382A1 (fr) 2002-10-02 2004-04-09 Sanofi Synthelabo Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
AU2004263179B8 (en) * 2003-08-08 2011-07-14 Vertex Pharmaceuticals Incorporated Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
US20050214751A1 (en) 2004-03-02 2005-09-29 Proteologics, Inc. Inhibition of viral maturation, methods and compositions related thereto

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014807A1 (en) * 2004-07-19 2006-01-19 Lin Leu-Fen H Neuroprotective small organic molecules, compositions and uses related thereto

Also Published As

Publication number Publication date
EP2083826A4 (en) 2010-09-22
AU2007318922B2 (en) 2013-01-10
US8283355B2 (en) 2012-10-09
WO2008056356A3 (en) 2009-09-03
CA2668859A1 (en) 2008-05-15
WO2008056356A2 (en) 2008-05-15
JP2010509205A (ja) 2010-03-25
EP2083826A2 (en) 2009-08-05
AU2007318922A1 (en) 2008-05-15
US20130131094A1 (en) 2013-05-23
US20100179178A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
AU2007318922C1 (en) Pyrimidine derivatives as POSH and POSH-AP inhibitors
Lu et al. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials
US9765019B2 (en) Small-molecule-targeted protein degradation
US7659277B2 (en) Ubiquitin ligase inhibitors and methods related thereto
AU2004268647B2 (en) Modulation of beta-catenin/TCF activated transcription
US20040259880A1 (en) Pyrrole compounds and uses thereof
US20120135089A1 (en) E3 ligase inhibitors
DK2780326T3 (en) PROCEDURE FOR INHIBITING DEUBIQUITINATION ACTIVITY
Donkor An update on the therapeutic potential of calpain inhibitors: a patent review
CN107531683A (zh) Usp7抑制剂化合物及使用方法
Blaquiere et al. Medicinal chemistry of inhibiting RING-type E3 ubiquitin ligases
CN114025766B (zh) 用于抑制gapdh的噁噻嗪化合物
US20120015967A1 (en) Pyrimidine and pyridine derivatives as posh and posh-ap inhibitors
WO2004078130A2 (en) Posh interacting proteins and related methods
AU2005279845A1 (en) Inhibition of viruses using RNase H inhibitors
US20060286630A1 (en) Posh interacting proteins and related methods
CN109790523A (zh) 组合物及其用途
Shouksmith Design and synthesis of small-molecule inhibitors targeting the SCFSKP2 E3 ligase and the MDMX-p53 interaction for cancer therapy
WO2004073609A2 (en) Posh associated kinases and related methods
Sharma Strategic improvements in efficacy of DNA damaging chemotherapeutic drugs through modulation of survival factors
HK1248684B (en) Usp7 inhibitor compounds and methods of use
WO2009063412A1 (en) Use of chemical compounds for the treatment of aids

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 APR 2013 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 09 APR 2013

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired